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Background: Fast and accurate etiologic diagnosis of pneumonia in immunocompromised
patients is essential for a good outcome. Utility of bronchoalveolar lavage (BAL) samples
has already been established, but studies about them are scarce and limited to few
countries. We aimed to evaluate the accuracy of a diagnostic protocol, emphasizing on
local epidemiology, rapidity, and yield of different techniques.
Methods: One year prospective study of 101 consecutive immunosuppressed patients
admitted with suspected pneumonia to a university hospital. They all had bronchoscopic
BAL (n ¼ 109) and respiratory sampling. Conventional microbiological studies, cytomega-
lovirus pp65 antigenemia and transbronchial biopsy (TBB), whenever considered pertinent,Elsevier Ltd. All rights reserved.
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Bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia 2161were done. Results were analyzed along with other diagnostic procedures, clinical course
and final outcome.
Results: HIV/AIDS infection was the most frequent cause of inclusion (n ¼ 80). Infections
accounted for 79 out of 122 final diagnoses (64.8%). Our protocol identified 60 infectious
and 3 noninfectious pathologies (general yield: 51.6%). Sensitivity in pulmonary infections
was 75.9% (IC95%: 64.8–84.6%), specificity 86.0% (72.6–93.7%), positive predictive value
89.6% (79.1–95.3%), negative predictive value 69.4% (56.2–80.1%), accuracy 79.8%
(71.7–86.2%). Mycobacterium spp. (n ¼ 27), bacteria (n ¼ 19), Pneumocystis jirovecii
(n ¼ 18) and other fungi (histoplasmosis: 6, aspergillosis: 5, cryptococosis: 3) were the
most common infectious pathogens. Direct microscopy allowed an early definite/
presumptive diagnosis in 36/49 fungal and mycobacterial infections (73.5%). Up to 30%
of mycobacterial infections were missed.
Conclusions: Systematical study of BAL samples has a high diagnostic yield in our
immunocompromised patients with suspected pneumonia. As economical and epidemio-
logical conditions of regions are different, it should be tried everywhere.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pneumonia is a major cause of morbidity and mortality in
immunosuppressed patients.1–3 Rapid diagnosis and early
treatment are necessary for a good outcome.1,4 However,
accurate microbiological diagnosis is challenging as many
infectious and noninfectious conditions have comparable
clinical presentation.1,2,5–8
Flexible bronchoscopy (FB) with bronchoalveolar lavage
(BAL) is simple, safe, fast and reliable. It has been
extensively used as diagnostic procedure for assessing
immunosuppressed hosts with pulmonary infiltrates.7,9–14
BAL sensitivity and specificity are comparable to other
techniques.15 Ideally, a clinician should submit BAL samples
to a single microbiology laboratory, results of histochemical
stains should be available within hours of specimen submis-
sion, and a report summarizing all of the information
obtained from analysis should be issued from that labora-
tory.9 Several groups have already demonstrated the clinical
value of BAL protocols, particularly when samples are
methodically studied.7,9,10,16–18 However, they are limited
to few countries.
Local data in Latin America, specifically in Colombia, are
scarce.19,20 This study was conducted to evaluate the role of
systematic analysis of BAL samples in the etiologic assess-
ment of immunosuppressed patients with pneumonia, in a
region with different social, economical and epidemiological
patterns. In order to optimize the process, and elaborate
guidelines for empirical treatment in these cases, we
emphasized on the protocol diagnostic accuracy, rapidity
to preliminary diagnosis, specific problems with some
pathogens, and differences with other countries reports.Materials and methods
Patient population
We included 101 immunosuppressed patients consecutively
admitted to Hospital Universitario San Vicente de Pau´l
(HUSVP, Medellı´n-Colombia) with suspected pneumonia from
June 2000 to July 2001. Patients older than 12 years wereincluded if they had at least one of the following symptoms:
cough, dyspnea, abnormal auscultatory findings and new
pulmonary infiltrates. Immunosuppression was considered if:
HIV infection or AIDS; neutropenia o500 cells/mm3, bone
marrow or solid organ transplantation, hematological
malignancies, immunosuppressive treatment (prednisone
0.3mg/k/d, or its equivalent, longer than 2 weeks),
noncontrolled diabetes and splenectomy. The research team
had no control over treatment. All patients signed an
informed consent according to legal requirements (Colombia
Ministry of Health Resolution 008430, 1993), and the study
was approved by University of Antioquia Ethics Committee
and HUSVP Internal Review Board. Exclusion criteria were
pregnancy, severe heart arrhythmia, serious hemoptysis,
instable hemodynamic status, critical respiratory failure
(PaO2/FiO2o120) and any other condition with risk for
bronchoscopic procedures.
Bronchoalveolar lavage and respiratory sampling
FB and BAL were performed following American Thoracic
Society guidelines.21 Transbronchial biopsy (TBB) was done
in case of diffuse interstitial or reticulonodular infiltrates (at
pulmonologist’s discretion), whenever the patient had no
contraindications for it (platelet countp50,000/mm3, in-
creased coagulation times, significant pulmonary hyperten-
sion, or poor functional respiratory reserve). An open-lung
biopsy was carried out if BAL studies were no diagnostic and
clinical conditions allowed it.
Laboratory processing of specimens
Each specimen was quantitatively cultured for bacteria on
conventional agar media. All isolates containing X103
colony forming units (CFU)/ml were identified to specie. In
general, BAL specimens were considered significant if they
contained X104 CFU and p1% squamous epithelial cells in
Wright-stained slides.9,22–24 After quantitative cultures were
set up, specimens were centrifuged at 1500g for 20min at
4 1C. Pellets were partitioned. A portion was plated for
fungus (incubated at 30 1C in aerobic conditions for 4 weeks
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Table 1 Criteria to determine whether an identified
infectious agent on BAL was a true pathogen.7,10,15,16,26
1 Any positive stain and/or isolation of P. jirovecii,
M. tuberculosis and H. capsulatum.
2 Isolation of any recognized bacterial pulmonary
pathogen on a quantitative culture X104 CFU/ml
and epithelial squamous cells p1%. Also, any
bacterial growth was considered significant in
patients who were on appropriate antibiotics for the
isolated bacteria within the previous week, as long
as the Gram stain was compatible and no other
L. Ve´lez et al.2162on Mycosel, Girasol, and Sabouraud’s agar), and mycobac-
teria (at 37 1C in aerobic conditions for 6 weeks on Ogawa-
Kudoh medium and thin layer agar25). The other portion was
suspended in 4ml of Hanks salt solution and cytocentrifuged
at 1500 rpm for 15min (Cytospin III, Shandon Instruments,
Sewickley, PA) after adjusting to 105 cells/ml. Slides were
stained with Wright, Gram, Ziehl-Neelsen (ZN), modified
Kinyoun and modified toluidine blue (TBO), according to
Kahn–Jones’ protocol.9
Bronchial brushings, transbronchial and open lung biopsy
specimens were stained with hematoxylin–eosin, ZN and
Gomori-methenamine silver.etiology was demonstrated. If culture was negative
but the patient was on broad spectrum antibiotics
when BAL was performed, bacteria were considered
probable cause of pneumonia, as long as he/she
improved with, and no other causes accounted for
symptoms.
3 Isolation of Cryptococcus neoformans on BAL, when:
(i) it was isolated concurrently in other sterile body
fluid, such as blood or CSF; (ii) no other possible
pulmonary pathogen was isolated; or (iii) there was
tissue infiltration on histopathology.
4 Isolation of Aspergillus spp. in case of: (i)
neutropenia or hematological malignancies; (ii)
hemoptysis or alveolar hemorrhage; (iii) concurrent
isolation in other sterile body fluid, such as pleural
fluid; or (iv) tissue infiltration on pulmonary biopsy.Variables recorded
Conventional clinical and laboratory data with special
emphasis on type, stage and severity of immunosuppression,
antibiotic’s use within previous week of respiratory sam-
pling, and microbiological analysis of blood, sputum, urine,
pleural and spinal fluids. Cytomegalovirus (CMV) pp65
antigenemia assay was evaluated in all cases.
All in-patients were followed until discharge or death.
Survivors were followed up for 1 year through visits to the
infectious diseases clinic and/or by reviewing their clinical
charts. Telephone calls to patients, their families and
doctors in charge were tried when they did not return to
the hospital.5 Isolation of any nontuberculous mycobacteria when
there was no other pathogen accounting for the
pneumonia.
6 Histopathological evidence of pulmonary damage
due to invasive CMV or Candida spp.
BAL: bronchoalveolar lavage; CFU: colony forming units; CSF:
cerebrospinal fluid; CMV: Cytomegalovirus.Diagnostic criteria
To determine whether an identified microorganism on BAL
was a true pathogen, we applied strict diagnostic criteria
(Table 1). Besides that, etiology was established based on
other diagnostic procedures, clinical course and final
outcome. At least two of the clinical investigators evaluated
the information of every case. Unspecific airways inflam-
matory condition (UAIC) was defined by the presence of: (i)
cough without dyspnea, (ii) unspecific auscultatory findings
in absence of pulmonary infiltrates, (iii) spontaneous
improvement without specific treatment, and (iv) no
microorganisms isolated. Diagnoses of pulmonary fibrosis,
malignancies, pulmonary hypertension or edema were based
on clinical, radiographical and histopathological evaluation.
If patients had pulmonary infiltrates, but histopathological
and microbiological results were not conclusive, final
diagnosis was classified as unclear.Statistical analysis
Data were collected and analyzed using Epiinfo software,
version 6,04 (Epidemiology Program Office, CDC, Atlanta,
GA). Two-tailed Fisher’s exact test was used to compare
pairs of proportions. A P-valueo0.05 was considered
statistically significant. Sensitivity, specificity, positive and
negative predictive values (PPV–NPV), and accuracy (a+d/
a+b+c+d)27 were calculated using Epidat software, version
2,0 (Xunta de Galicia, Santiago de Compostela, Espan˜a).Results
Patients
During the study, 109 BAL procedures were performed in 101
patients. Table 2 displays basal features of them. HIV
infection was the cause of inclusion in 80 patients, 90% with
AIDS.28 Those with two or more causes of immunosuppres-
sion were included in the most relevant category at time
BAL was done.
Etiology of pulmonary symptoms
Table 3 shows the distribution of 122 final diagnoses.
The most common etiologies were mycobacteria (26.7%),
UAIC (23.8%, almost exclusively in AIDS patients), bacteria
(18.8%) and Pneumocystis jirovecii (17.8%). Predominant
etiology varied according to immunosuppression: Myco-
bacterium spp. (30%), UAIC (28.7%) and P. jirovecii
(21.2%) in HIV/AIDS patients, aspergillosis (27.3%) in
transplantation, and bacterial pneumonia (70%) in the
others.
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Table 2 Baseline characteristics of 101 immunosup-
pressed patients with suspected pneumonia.
Age (years)
Mean7SD (range) 34.1710.8 (13–75)
Sex
Male/female (%) 74/26
Type of immunosuppression
(1) HIV/AIDS, n (%) 80 (79%)
On HAART, n (%) 12 (15%)
T CD4+ lymphocytes count (n ¼ 47)
Mean, cells/mm37SD (range) 1287211 (2–1303)
Median (cells/mm3) 65
CD4+p200, n (%) 39 (83%)
CD4+4200, n (%) 8 (17%)
Viral load (n ¼ 45)
Mean, copies/mm37SD 313,2417282,914
o10,000, n (%) 3 (6.7%)
X10,000, n (%) 42 (93.3%)
(2) Transplantation patients, n (%) 11 (11%)
Kidney, n 10
Bone marrow, n 1
Days after transplantation,
mean7SD (range)
97071187
(50–4342)
Median (days) 611
(3) Others, n (%) 10 (10%)
Hematological malignancies,y n 6
Corticosteroids therapy, n 3
Neutropenia,z n 1

SD: standard deviation.
HAART: highly active antiretroviral therapy.
yHematological malignancies: Hodgkin disease (2 patients),
non-Hodgkin lymphoma (1), acute myeloid leukemia (1),
acute lymphoid leukemia (1), multiple myeloma (1).
zSecondary to gastrointestinal sepsis.
Bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia 2163Diagnostic accuracy of the protocol
Infections accounted for 79/122 (64.8%) final diagnoses
(Table 3). BAL samples allowed us to identify 97 agents,
60 of them considered true pathogens. Candida spp.
and bacteria were common colonizers (Fig. 1). Only 3 of
43 noninfectious pulmonary pathologies were diagnosed
by the protocol, all of them by TBB (Fig. 2). Thus, general
yield was 51.6% (63/122). In seven cases, microorganisms
initially identified on BAL as pathogens, were considered
misclassified by further analysis. According to Table 1,
sensitivity in pulmonary infections was 75.9% (IC95%:
64.8–84.6%), specificity 86.0% (72.6–93.7%), PPV 89.6%
(79.1–95.3%), NPV 69.4% (56.2–80.1%) and accuracy 79.8%
(71.7–86.2%). Sensitivity was 100% for P. jirovecii (18/18),
histoplasmosis (6/6) and cryptococcosis (3/3), 70.4% for
mycobacteria (19/27), 60% for aspergillosis (3/5) and 57.9%
for conventional bacteria (11/19) (Fig. 2). Direct microscopy
was positive in 36 of 49 patients (73.5%) with fungal and/or
mycobacterial pneumonia (P. jirovecii 18/18, mycobacteria10/19, histoplasmosis 3/6, aspergillosis 3/3 and cryptococ-
cosis 2/3).
Mycobacteria were considered the cause of pneumonia
in 27 patients, but this protocol only diagnosed 19:12
M. tuberculosis, 4 nontuberculous mycobacteria and 3 ZN-
positive, but culture-negative cases. Of eight patients
missed by the protocol, two had pulmonary tuberculosis
(TB) and six had extrapulmonary forms (two mediastinitis,
one pericarditis, one pleuritis, one lymphadenitis and one
gastrointestinal TB). Three were already on tuberculosis
treatment. Sensitivity of cultures and acid fast staining in
BAL samples was 59% (16/27) and 37% (10/27), respectively;
13 of 16 positive cultures grew in thin layer, 13 in Ogawa and
10 in both media. Time required to growth was 22710.7
days in Ogawa (range: 12–55; median: 20) and 14.376.0 in
thin layer (range: 4–26; median: 15).
BAL samples allowed to detect 11/19 patients with
bacterial pneumonia (57.9%). All cases not diagnosed by
BAL corresponded to partially treated infections (mean: 6
days, range: 2–12), which improved with prescribed anti-
biotics.
Histopathological studies were performed in 28 patients:
24 TBB, 3 open lung biopsies and 1 necropsy. TBB identified
13 of 23 infectious agents (56.5%) demonstrated in these 24
patients. Sensitivity was 50% (5/10) for mycobacteria, 33%
(2/6) for bacteria, 100% for P. jirovecii (3/3), and 75% for
other fungal infections (3/4).
Diagnostic fails
This protocol failed as a diagnostic tool in 59/122 (48.4%)
final conditions (Fig. 2); 19 (32%) were attributed
to infectious diseases (8 by bacteria, 8 mycobacteria,
2 aspergillus, 1 CMV), and 36 (61%) to noninfectious
pathologies (24 cases of UAIC, 5 fibrosis, 4 malignancies,
2 edema and 1 case due to pulmonary hypertension). It
was impossible to define the cause of pneumonia in 4
patients (7%).
Diagnostic yield of other procedures
CMV disease was demonstrated in seven patients (six AIDS
and one kidney transplant recipient). Of them, three had
retinitis, three had colitis (by biopsy) and one, the
transplantation case, had pneumonia associated to central
nervous system involvement (by necropsy). Among these
patients, antigenemia assay was negative in 4, low-positive
in 2 (o10 positive cells/150,000 leukocytes) and highly
positive (180/150,000) in 1 case (CMV ulcerative colitis). On
the other hand, only 1 of 13 patients with pp65X10 cells/
150,000 leukocytes had CMV disease.
Chest X-rays had no significant value to predict the
etiology of infection.
Discussion
Systematical study of BAL samples leads to accurate and
opportune diagnosis of etiology in immunosuppressed
patients with suspected pneumonia.1–4,29 We found a
general yield of 51.6%, but 75.9% in infectious diseases.
These results are very similar to previous reports from
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Figure 1 Distribution of the different germs isolated in BAL samples (n ¼ 109) in 101 immunosuppressed patients with suspected
pneumonia. Black bars correspond to microorganisms considered true pulmonary pathogens, and striped bars to colonizers, according
to criteria displayed in Table 1. Numbers in front of bars represent the percentage of each isolated microorganism considered true
pathogen.
Table 3 Etiology of 122 final diagnoses in 109 BAL procedures made to 101 patients, according to type of immuno-
suppression.
Final diagnosis, n (%) HIV/AIDS (n ¼ 80) Transplant (n ¼ 11) Others (n ¼ 10) Total (n ¼ 101)
Mycobacterial infection 24 (30.0) 2 (18.2) 1 (10.0) 27 (26.7)
UAICy 23 (28.7) 1 (9.1) 0 24 (23.8)
Bacterial pneumonia 11 (13.7) 1 (9.1) 7 (70.0) 19 (18.8)
P. jirovecii 17 (21.2) 1 (9.1) 0 18 (17.8)
Histoplasmosis 5 (6.2) 1 (9.1) 0 6 (5.9)
Pulmonary fibrosis 3 (3.7) 2 (18.2) 1 (10.0) 6 (5.9)
Aspergillosis 0 3 (27.3) 2 (20.0) 5 (4.9)
Unclear cause 2 (2.5) 2 (18.2) 0 4 (4.0)
Malignancy infiltrationz 1 (1.2) 0 3 (30.0) 4 (4.0)
Pulmonary edema 2 (2.5) 2 (18.2) 0 4 (4.0)
Cryptococcosis 3 (3.7) 0 0 3 (3.0)
Pulmonary hypertension 1 (1.2) 0 0 1 (1.0)
Cytomegalovirus 0 1 (9.1) 0 1 (1.0)
Total diagnoses,y n 92 16 14 122
Infections, n (%) 60 (65.2) 9 (56.2) 10 (71.4) 79 (64.8)
Others: hematological malignancies (6 patients), on therapy with corticosteroids (3), neutropenic patient (1).
Mycobacterial infections: tuberculosis (19 patients), nontuberculous mycobacteria (4), culture negative cases (4).
yUAIC: unspecific airways inflammatory condition (see ‘‘Diagnostic criteria’’ in Materials and Methods).
zMalignancy infiltration of lung: Kaposi sarcoma (1 case in a HIV/AIDS patient), anaplastic lymphoma (1), Hodgkin disease (1),
multiple myeloma (1).
yTotal diagnoses: the sum of each column is greater than the number of patients in each category as several patients had more than
one diagnosis.
L. Ve´lez et al.2164United States7,9,10,14 and Spain,16,17, whose general yield
was 51–60%; for pulmonary infections was 52–81%, and the
proportion due to infectious diseases 61–72% (65% in our
study).
Distribution of pulmonary pathogens depends on the
epidemiology of each region. In this study, Mycobacterium
spp., mainly tuberculosis, affected one of every fourimmunosuppressed patients with pneumonia, unlike devel-
oped countries, where it involves 2–4% of them.7,9,10,16,17
It explained one-third of infections identified in this study
(27/79, 34.2%). Previous studies in Colombia also pointed TB
as the most frequent opportunistic infection, complicating
15–25% of AIDS patients.19,30 TB represents a serious public
health threat in our country (incidence among 25–4931 and
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Figure 2 Definitive diagnoses in 101 immunosuppressed patients with suspected pneumonia. Black bars correspond to 63 diagnoses
made by our protocol (including TBB when it was considered pertinent); striped bars represent 59 diagnoses in which the protocol
was of no help. Total number of diagnoses was greater than 101 as several patients have more than one diagnosis. Figures in front of
bars are the percentage of every diagnosis made by our protocol: (1) unspecific airways inflammatory condition; (2) bronchoalveolar
lavage; (3) transbronchial biopsy.
Bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia 216550–84/100,00032) and all tropical Latin American region.32
Furthermore, the magnitude of the problem can be even
worse because diagnosis is still elusive (the protocol missed
8/27 mycobacterial infections, 29.6%). There are several
possible explanations for these false negative cases: (i) 3/8
were on TB treatment when BAL was carried out (on the 1st,
2nd and 5th month, respectively) and (ii) presence of
interstitial more than alveolar involvement. Unfortunately,
many clinicians do not use to culture pulmonary tissue; and
(iii) we did not make TBB to everyone in the study. However,
histopathological yield for mycobacteria was only 50%. Our
results highlight the importance of other diagnostic tools,
such as blood/tissue cultures and polymerase chain reaction
(PCR) in BAL samples. Meanwhile, in high prevalence
regions, clinicians should consider the empirical use of TB
treatment, especially when no other pathogen is found
responsible.
Frequency of histoplasmosis was similar to reports from USA
in HIV patients,10 but greater than in Spain16 and non-HIV
immunocompromised hosts.9,14,17 On the other hand, inci-
dence of bacterial pneumonia (17%) and P. jirovecii (16%) were
within percentages reported elsewhere (7–27% and 2–47%);
however, the occurrence of bacteria in our protocol (17%)
could be underestimated by use of broad spectrum antibiotics
before processing BAL samples.22,33 In fact, all eight patients
with bacterial pneumonia, whose diagnosis was missed, were
on antibiotics at the time of BAL (mean: 6 days).
Direct stains from most patients with fungal and
mycobacterial infections were reported as positive withinthe first 6 h after BAL (36/49, 73.5%). These preliminary
results were timely enough to start early treatment. The
faster growth of mycobacteria in thin layer agar than in
Ogawa medium sped up 1 week identification and suscept-
ibility testing of mycobacteria.
Noninfectious diseases explained most of missed diag-
nosis, as has also been reported elsewhere7 (Fig. 2). UAIC
was the most common cause in our cases; it occurred in
patients with decreased level of consciousness, whose
impossibility to deal with bronchial secretions gives them
cough and abnormal auscultatory findings. Most had oppor-
tunistic AIDS-related infections (such as CMV or toxoplasma
encephalitis) and severe AIDS–dementia complex. They all
got better after improving their respiratory hygiene and
neurological conditions.
Our study had two important limitations. First, we did not
include diagnostic assays to rule out the presence of
‘‘atypical’’ germs and/or respiratory viruses. According to
previous studies,9,16,17,34 pneumonia could be caused by
these agents in 17–19% of immunosuppressed patients.
Nevertheless, several facts suggest it should not be a
problem in our population. First, it is known that CMV
is not a frequent cause of pneumonia in HIV/AIDS patients,
who represented the majority of individuals involved
(80/101).16 Secondly, Legionella spp. and Chlamydophila
pneumoniae do not seem to be a big problem in South
America, although information about them is limited35;
and Mycoplasma pneumoniae is not especially common in
these patients.16,17 Finally, there was not a documented
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L. Ve´lez et al.2166Colombian outbreak of viral infections in population older
than 12 years during the study.36 Although it is still possible
that any of these agents explained some cases, our data
suggest that they would have no significant impact on the
results.
A second limitation is the lack of a reliable ‘‘gold
standard’’ test in this setting, limitation shared by all
prior studies. However, we believe that, as usually done
in clinical practice, reaching the final diagnosis based
on strict criteria, including clinical course and outcome,
allows us to provide useful data about the diagnostic
accuracy of our protocol, main goal of the study. On the
other hand, it would have been very useful to determine the
impact of the protocol on time to recovery, morbidity and
mortality. But our design, exclusively conceived to deter-
mine etiology, does not provide an answer to that question.
That is something that will have to be done in the next
future.
CMV antigenemia assay did not seem to play any
important role in our patients. It has been described an
association between high systemic CMV load and CMV
disease in HIV-infected individuals and solid-organ trans-
plantation, but correlation is inconsistent, and some
patients with low/undetectable systemic viral load can
develop CMV disease.37 Although antigenemia assay has
shown good results in some immunosuppressed patients and
several institutions including ours,38,39 these results support
that other factors like viral virulence and tropism, dis-
semination ability of certain genotypes, and CMV-specific
immunity may be important for the development of CMV
disease.37 To determine its role in these patients, it would
have been necessary to measure CMV load in BAL samples
and correlate these findings with those coming from
traditional and shell vials cultures.
Our findings point to some issues that have to be studied
in future research. First, it is required to clarify the real role
of atypical germs and respiratory viruses in immunocompro-
mised patients, and the contribution of microbiological
cultures of TBB and PCR testing in BAL samples for
diagnosing mycobacterial and fungal diseases. Second,
because an invasive procedure such as a FB may be unsafe
in some critically ill patients, it is important to evaluate the
diagnostic accuracy of nonbronchoscopic BAL under these
circumstances.
In conclusion, our findings highlight that as economical
and epidemiological conditions of regions are different,
systematical study of immunosuppressed patients with
suspected pneumonia should be tried everywhere. Oppor-
tune and accurate results are very useful for affected
patients, clinicians, insurance companies and health autho-
rities involved in care-giving activities and local guidelines
development. Furthermore, in high incidence regions of
tuberculosis, rapid identification and treatment of potential
sources will allow better control of this kind of nosocomial-
acquired infections.Conflict of interest
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